Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wick, C
Right arrow Articles by Tyler, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wick, C
Right arrow Articles by Tyler, L.
American Journal of Health-System Pharmacy, Vol 60, Issue 22, 2314-2320
Copyright © 2003 by American Society of Health-System Pharmacists

Articles

Using a closed-system protective device to reduce personnel exposure to antineoplastic agents

C Wick, MH Slawson, JA Jorgenson, and LS Tyler


Surface contamination with and personnel exposure to antineoplastic agents before and after the implementation of a closed-system protective device were studied. Samples were collected before and six months after implementation of PhaSeal, a closed-system device for limiting exposure to antineoplastic agents during preparation and administration. Personnel exposure was evaluated by collecting 24-hour urine samples from pharmacists, pharmacy technicians, and nurses working full-time in a chemotherapy drug infusion center and pharmacy. Surface contamination was assessed by wiping potentially exposed surfaces. Both types of samples were analyzed for cyclophosphamide and ifosfamide by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry. All 17 wipe samples collected before implementation of PhaSeal had detectable levels of cyclophosphamide, and 11 were positive for ifosfamide. Six months after system implementation, 7 of 21 wipe samples had detectable levels of cyclophosphamide and 15 were positive for ifosfamide. Of eight employees who provided urine samples, six were positive for cyclophosphamide and two for ifosfamide before implementation, and none were positive for either drug after implementation. The PhaSeal system appeared to reduce exposure of health care personnel to cyclophosphamide and ifosfamide.
 



This article has been cited by other articles:


Home page
 J Oncol Pharm PractHome page
Section 1 Introduction
Journal of Oncology Pharmacy Practice, September 1, 2007; 13(3_suppl): 3 - 6.
[PDF]

Home page
 J Oncol Pharm PractHome page
Section 7 Special devices
Journal of Oncology Pharmacy Practice, September 1, 2007; 13(3_suppl): 27 - 30.
[PDF]

Home page
 J Oncol Pharm PractHome page
Section 10 Chemical contamination monitoring
Journal of Oncology Pharmacy Practice, September 1, 2007; 13(3_suppl): 44 - 48.
[PDF]

Home page
 CA Cancer J ClinHome page
T. H. Connor and M. A. McDiarmid
Preventing Occupational Exposures to Antineoplastic Drugs in Health Care Settings
CA Cancer J Clin, November 1, 2006; 56(6): 354 - 365.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
B. R. Harrison, B. G. Peters, and M. R. Bing
Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques.
Am. J. Health Syst. Pharm., September 15, 2006; 63(18): 1736 - 1744.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
ASHP Guidelines on Handling Hazardous Drugs
Am. J. Health Syst. Pharm., June 15, 2006; 63(12): 1172 - 1191.
[Full Text] [PDF]

Home page
 Int J Qual Health CareHome page
P. Bonnabry, L. Cingria, M. Ackermann, F. Sadeghipour, L. Bigler, and N. Mach
Use of a prospective risk analysis method to improve the safety of the cancer chemotherapy process
Int. J. Qual. Health Care, February 1, 2006; 18(1): 9 - 16.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
T. H. Connor, P. J. M. Sessink, B. R. Harrison, J. R. Pretty, B. G. Peters, R. M. Alfaro, A. Bilos, G. Beckmann, M. R. Bing, L. M. Anderson, et al.
Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: Results of three studies
Am. J. Health Syst. Pharm., March 1, 2005; 62(5): 475 - 484.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Society of Health-System Pharmacists.